{
    "nctId": "NCT00217659",
    "briefTitle": "S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of Goserelin Plus Anastrozole for the Treatment of Male Patients With Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Recurrent or metastatic (stage IV) disease\n\n    * Patients with a local regional recurrence, including axillary and/or chest wall involvement, are eligible\n* Measurable or non-measurable disease\n* Brain metastases allowed provided they have been treated with surgery or radiotherapy AND have remained stable for \u2265 3 months\n* Hormone receptor status:\n\n  * Estrogen receptor- OR progesterone receptor- positive disease by standard immunohistochemical techniques\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male\n\nPerformance status\n\n* Zubrod 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* No evidence of severe or uncontrolled hepatic disease\n\nRenal\n\n* No evidence of severe or uncontrolled renal disease\n\nCardiovascular\n\n* No evidence of severe or uncontrolled cardiac disease\n\nPulmonary\n\n* No evidence of severe or uncontrolled respiratory disease\n\nOther\n\n* Fertile patients must use effective barrier-method contraception during and for 12 weeks after the completion of study treatment\n* No known HIV positivity\n* Able to receive oral medication\n\n  * Patients with a gastrointestinal tube are eligible\n* No known hypersensitivity to luteinizing hormone-releasing hormone (LHRH), LHRH agonist analogues, or any components of the study drugs\n* No active infection requiring systemic therapy\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer\n* No evidence of other severe or uncontrolled systemic disease\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No concurrent prophylactic filgrastim (G-CSF) or other hematopoietic growth factors\n\nChemotherapy\n\n* At least 14 days since prior chemotherapy for this cancer and recovered\n* No more than 1 prior chemotherapy regimen for metastatic disease\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* At least 14 days since prior hormonal therapy for this cancer and recovered\n* Prior tamoxifen allowed\n* No prior gonadotropin-releasing hormone antagonist, aromatase inhibitors, or fulvestrant\n* No other concurrent hormonal therapy (e.g., estrogen-based therapies)\n\nRadiotherapy\n\n* See Disease Characteristics\n* At least 14 days since prior radiotherapy for this cancer and recovered\n* No concurrent radiotherapy\n\nSurgery\n\n* See Disease Characteristics",
    "sex": "MALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}